Children's Hospital of Chicago Research Center, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, 225 E. Chicago Avenue, Box 222, Chicago, IL 60611, USA.
Cancer Metastasis Rev. 2012 Dec;31(3-4):529-51. doi: 10.1007/s10555-012-9361-0.
Maspin, a non-inhibitory member of the serine protease inhibitor superfamily, has been characterized as a tumor suppressor gene in multiple cancer types. Among the established anti-tumor effects of Maspin are the inhibition of cancer cell invasion, attachment to extracellular matrices, increased sensitivity to apoptosis, and inhibition of angiogenesis. However, while significant experimental data support the role of Maspin as a tumor suppressor, clinical data regarding the prognostic implications of Maspin expression have led to conflicting results. This highlights the need for a better understanding of the context dependencies of Maspin in normal biology and how these are perturbed in the context of cancer. In this review, we outline the regulation and roles of Maspin in normal and developmental biology while discussing novel evidence and emerging theories related to its functions in cancer. We provide insight into the immense therapeutic potential of Maspin and the challenges related to its successful clinical translation.
Maspin 是丝氨酸蛋白酶抑制剂超家族的非抑制性成员，已被确定为多种癌症类型的肿瘤抑制基因。Maspin 的已确定的抗肿瘤作用包括抑制癌细胞侵袭、与细胞外基质的附着、增加对细胞凋亡的敏感性以及抑制血管生成。然而，尽管大量的实验数据支持 Maspin 作为肿瘤抑制因子的作用，但有关 Maspin 表达的预后意义的临床数据却导致了相互矛盾的结果。这突出表明需要更好地了解 Maspin 在正常生物学中的背景依赖性，以及在癌症背景下这些依赖性是如何受到干扰的。在这篇综述中，我们概述了 Maspin 在正常和发育生物学中的调节和作用，同时讨论了与其在癌症中的功能相关的新证据和新兴理论。我们深入了解了 Maspin 的巨大治疗潜力以及成功临床转化所面临的挑战。
